NCT03759379 : HELIOS-A: A Phase 3 Global, Randomized, Open-label Study to Evaluate the Efficacy and Safety of ALN-TTRSC02 in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis)

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

ThreePhase Three

18-85Age 18-85

Blood<br/>CancersCancer LocationBlood
Cancers

Systemic therapy | Blood / Myeloma / LymphomaAmyloidosis

Trial Overview Read MoreRead more

This Phase III is evaluating the effectiveness of a targeted therapy (vutrisiran) in people with hereditary transthyretin amyloidosis.
 

This trial is treating patients with hereditary transthyretin amyloidosis (hATTR amyloidosis).

This is a systemic therapy trial.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have had certain treatments, surgical procedures or drugs.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

HELIOS-A: A Phase 3 Global, Randomized, Open-label Study to Evaluate the Efficacy and Safety of ALN-TTRSC02 in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis)

Commercial Sponsor

Alnylam Pharmaceuticals

Summary

Vutrisiran (ALN-TTRSC02) : Participants will receive vutrisiran during the Treatment and Treatment Extension Periods. Drug: Vutrisiran (ALN-TTRSC02) : Patisiran will be administered by intravenous (IV) infusion.

Recruiting Hospitals Read MoreRead more

Box Hill Hospital, Malignant Haematology
Box Hill
Ms Lesley Poulton
lesley.poulton@monash.edu
03 9094 9502

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next